Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;5(1):73-9.
doi: 10.1007/s40121-016-0104-3. Epub 2016 Mar 2.

Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen

Ursula C Patel  1 , David P Nicolau  2 , Rabeeya K Sabzwari  3   4
Affiliations

Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen

Ursula C Patel et al. Infect Dis Ther. 2016 Mar.

Abstract

Introduction: Ceftolozane/tazobactam (C/T) is a novel antibiotic approved for complicated intra-abdominal and urinary tract infections caused by Gram-positive and Gram-negative organisms, including some MDR strains. Little is known about the use of this agent for treatment of bacteremia and even less so about the appropriateness of the renally defined regimens. We describe a case of a 66-year-old man with a history of chronic kidney disease (baseline Cr = 3-4 mg/dl) and recurrent nephrolithiasis with bilateral stents who had positive concurrent urine and blood cultures for MDR Pseudomonas aeruginosa (PSA), susceptible only to amikacin and colistin. Due to the MDR phenotype and his underlying kidney disease, the 375 mg (250 mg/125 mg) dose of C/T was given as monotherapy every 8 h for his bloodstream infection.

Methods: Once steady state was anticipated, blood was obtained at the end of infusion (1 h), and at 3, 5 and 8 h for drug concentration determination using a validated high-performance liquid chromatography method at the Center for Anti-Infective Research and Development, Hartford Hospital, Hartford.

Results: The minimum inhibitory concentration (MIC) for the PSA was 2/4 for C/T, indicating susceptibility. Concentration of ceftolozane of 21.87 µg/ml at 8 h indicated that serum concentrations were maintained above the MIC throughout the dosing interval. The patient was given 25 days of C/T and experienced a successful clinical outcome. Blood cultures obtained at 1 and 3 weeks after completion of treatment remained sterile. No adverse events were attributed to C/T.

Conclusion: In this patient, the renally adjusted dose of C/T was safe and provided sufficiently high drug concentrations that exceeded the MIC of the infecting organism over the course of therapy. More data are required to determine the clinical utility of C/T in the setting of MDR PSA bacteremia.

Keywords: Bacteremia; Ceftolozane/tazobactam; Multi-drug resistant; Pseudomonas aeruginosa.

PubMed Disclaimer

References

    1. Cubist Pharmaceuticals US Zerbaxa (ceftolozane/tazobactam) package insert. Lexington, MA; 2014.
    1. Sutherland CA, Nicolau DP. Susceptibility profile of Ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa from US Hospitals. Clin Ther. 2015;37(7):1564–1571. doi: 10.1016/j.clinthera.2015.05.501. - DOI - PubMed
    1. Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination. Pharmacotherapy. 2015;35(7):701–715. doi: 10.1002/phar.1609. - DOI - PubMed
    1. US National Institutes of Health. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02070757?term=ceftolozane+taz.... Accessed October 28, 2015.
    1. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI) Lancet. 2015;385:1949–1956. doi: 10.1016/S0140-6736(14)62220-0. - DOI - PubMed

LinkOut - more resources